Organization
Novartis Institutes for BioMedical Research
5 abstracts
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).Org: University Hospitals Leuven, Leuven, Belgium, Vall d’Hebron University Hospital/VHIO, Department of Oncology, National Taiwan University Hospital, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Centre Singapore,
Abstract
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).Org: BC Cancer - Vancouver Centre, Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Regina Elena,
Abstract
Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.Org: BC Cancer-Vancouver Centre, Vancouver Prostate Centre, Tulane Cancer Center, Gustave Roussy Institute, Memorial Sloan Kettering Cancer Center,
Abstract
A randomised, double-blind study to assess the safety, tolerability and preliminary efficacy of leniolisib (CDZ173) in patients with primary sjÖgren’s syndromeOrg: Department Medicine/Rheumatology and Clinical Immunology Charite Universitätsmedizin, Charité Research Organisation GmbH, Berlin, Germany, Medical University of Debrecen, Ungarn, Hungary, Novartis Institutes for Biomedical Research NOVARTIS,